Wang Y, Wang Y, Chen R, et al. - This study was undertaken to investigate the relationship between pretreatment plasma fibrinogen (Fib) level and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients and to assess the role of plasma Fib as a predictive factor. Researchers retrospectively examined data of 1,004 consecutive patients with invasive breast cancer who received NAC and subsequent surgery. They conducted both univariate and multivariate analyses based on logistic regression models to distinguish clinicopathological factors correlated with pCR to NAC. They used Cox regression models to ascertain the association between clinical or pathological parameters and recurrence-free survival. They used the Kaplan-Meier method and the log-rank test in the survival analysis. The findings illustrate that low pretreatment plasma Fib (Fib < 3.435 g/L) is an independent predictive factor for pCR to NAC in breast cancer patients. Furthermore, compared with high Fib status, T3-featured breast cancer patients with lower Fib level exhibit better RFS outcomes after NAC.